Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06973109Phase 2Not Yet Recruiting

Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes

Role: lead

NCT06704919Recruiting

Conduit Cages and Fibergraft BG Putty

Role: lead

NCT06704906Recruiting

Adult Patient Outcomes After Spine Surgery With Fibergraft BG Putty/Viper Prime

Role: lead

All 3 trials loaded